Trial Profile
A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs VCN 01 (Primary)
- Indications Retinoblastoma
- Focus Adverse reactions
- 25 Mar 2024 According to Theriva Biologics media release, the company has completed patient treatment.
- 25 Mar 2024 According to Theriva Biologics media release, the company expect complete patient follow-up in H1 2024.
- 29 Mar 2022 Planned End Date changed from 30 Apr 2021 to 30 Jun 2022.